HopeStage
Back to all studies
Not recruitingISRCTN64695913

Safety and efficacy trial of two doses of lurasidone in acutely psychotic subjects with schizophrenia (PEARL 3)

Research studyAges 18+Multiple countries
The study in practice

Understand this study

Who could participate?

This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.

Listed locations
Colombia · Germany and 6 more locations

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Not recruiting
Enrollment listed in the registry
Not clearly listed
Sponsor
Dainippon Sumitomo Pharma America Inc. (USA)
Sponsor type
Pharmaceutical company
Study type
Other
Intervention type
Other / unclear
Locations
United States, Colombia, Germany, ...
Age range
Over 18 Years
Official registry ID
ISRCTN64695913
Official title
Show the full official title

Safety and efficacy trial of two doses of lurasidone in acutely psychotic subjects with schizophrenia (PEARL 3)

Recruitment & locations

Not recruiting

Colombia · Germany · India

5 more locations
  • Philippines
  • Romania
  • Russia
  • Ukraine
  • United States

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Dainippon Sumitomo Pharma America Inc. (USA), a pharmaceutical company.

Who can participate?

This study is for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as not recruiting.

Want to explore more studies?

Explore studies